Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CDC6
REST API REST API
Homo sapiens
CDC6 is differentially expressed in 321 experiments: 109 organism parts: bone marrow, blood, ... (107 more);, 229 disease states: normal, adenocarcinoma, ... (227 more);, 107 cell types 381 cell lines 47 compound treatments and 79 other conditions.
Synonyms CDC18L
Orthologs CDC6 (Danio rerio)   Cdc6 (Mus musculus)   CDC6 (Bos taurus)   ENSCING00000001669 (Ciona intestinalis)   CDC6 (Saccharomyces cerevisiae)   Cdc6 (Rattus norvegicus)   Cdc6 (Drosophila melanogaster)   cdc6 (Xenopus laevis)   CDC6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, spindle midzone, spindle pole, cell division, DNA replication checkpoint, protein binding, cytoplasm, nucleoside-triphosphatase activity, negative regulation of cell proliferation, mitotic cell cycle, regulation of cyclin-dependent protein kinase activity, kinase binding, negative regulation of DNA replication, ATP binding, spindle, G1/S transition of mitotic cell cycle, nucleus, mitosis, nucleotide binding, chromatin binding, nucleoplasm, cell cycle checkpoint, S phase of mitotic cell cycle, DNA replication, traversing start control point of mitotic cell cycle, positive regulation of chromosome segregation, regulation of transcription involved in G1/S phase of mitotic cell cycle, regulation of mitotic anaphase, positive regulation of cell cycle cytokinesis, M/G1 transition of mitotic cell cycle
InterPro Term ATPase_AAA+_core, ATPase_AAA_core, Cdc6_C, Cell_div_Cdc6
UniProt Accession Q99741
Gene-Disease Assocation MEIER-GORLIN SYNDROME 5; MGORS5
Search EB-eye ENSG00000094804
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (32 experiments)

Factor Value U/D Experiments
H1437
2
E-GEOD-16194, E-MTAB-62
BT474
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-19639
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
375 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
CD4+ T cell
1
4
E-GEOD-16190, E-AFMX-5, E-MTAB-24, E-TABM-145, E-MTAB-25 ... (5 experiments)
centroblast
2
E-GEOD-15271, E-TABM-702
2
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
macrophage
1
E-GEOD-5099
101 more value(s).


Disease state

studied in E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (70 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
glioblastoma
2
E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
1
2
E-GEOD-2514, E-MTAB-62, E-MEXP-231
Nodular Goiter
1
E-MEXP-2442
223 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, ... (31 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
ethanol
2
E-MEXP-2241, E-GEOD-3113
unknown
1
E-GEOD-7307
valproic acid
1
E-GEOD-1615
Cxcl12
1
E-GEOD-7307
4OH-tamoxifen
1
E-GEOD-2292
41 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
43
1
1
E-GEOD-3494
40
1
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2191, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-18005, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-TABM-440, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-TABM-15, E-GEOD-16363, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, ... (9 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-2018, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22369, E-GEOD-33562, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-6532, E-GEOD-4922, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.27 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM